
Today is a special day for Relay Therapeutics. The FDA has approved lirafugratinib (brand name LYRFIGTU™) for patients with FGFR2-driven #cholangiocarcinoma, brought to patients by our commercial partner Elevar Therapeutics following our global out-licensing agreement in 2024. This is the first medicine to emerge from our Dynamo® platform, our approach to studying protein motion with the goal of solving some of the toughest challenges in drug discovery. Relay was founded to make medicines for patients in need, and reaching an approval just 10 years later makes this a landmark validation for our R&D team's approach. Kudos and Yahzu to the dedicated Relayers who worked relentlessly to discover and develop this drug, congratulations to our partners at Elevar, and a sincere thank you to the patients, families, and investigators who have made this accomplishment possible.
Breaking news! The FDA has approved our treatment for patients with previously treated, unresectable, locally advanced or metastatic cholangiocarcinoma (CCA) harboring a FGFR2 fusion or other rearrangement. Read our #ElevarPressRelease: elevartx.com/2026/09/23/elev… #ElevarTx #ElevarTherapeutics #ElevatingOutcomes #news






















